Clinical trial • Dermatology
Autologous bone marrow mononuclear cells for Hard-to-heal wounds|Difficult-to-heal wounds|Delayed wound healing
Clinical trial of Autologous bone marrow mononuclear cells for Hard-to-heal wounds|Difficult-to-heal wounds|Delayed wound healing. 10 participants.
Overview
- Trial Therapeutic Area
- Dermatology
- Trial Disease
- Hard-to-heal wounds|Difficult-to-heal wounds|Delayed wound healing
- Drug Modality
- Cell therapy
Key dates
- Initial CTIS Submission Date
- 04-12-2023
- First CTIS Authorization Date
- 22-03-2024
Trial design
Clinical trial across 1 site in Spain.
- Target Sample Size
- 10
Eligibility
Recruits 10 Vulnerable population not selected; no special consent/assent handling mentioned in the record..
- Vulnerable Population
- Vulnerable population not selected; no special consent/assent handling mentioned in the record.
Recruitment
- Planned Sample Size
- 10
- Recruitment Window Months
- 6
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 10
Spain
- Earliest CTIS Part Ii Submission Date
- 12-12-2023
- Latest Decision Or Authorization Date
- 08-05-2025
- Processing Time Days
- 513
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- Hospital Universitario Central De Asturias
- Department Name
- Unidad de Terapia Celular y Medicina Regenerativa
- Principal Investigator Name
- Silvia Perez Lopez
- Principal Investigator Email
- silvia.perez@sespa.es
- Contact Person Name
- Silvia Perez Lopez
- Contact Person Email
- silvia.perez@sespa.es
- Number Of Participants
- 10
Sponsor
Primary sponsor
- Full Name
- Fundacion Para La Investigacion Y La Innovacion Biosanitaria Del Principado De Asturias
- Organisation Type
- Laboratory/Research/Testing facility
- Country Of Registered Address
- Spain
Investigational products
- Investigational Product Name
- Autologous bone marrow mononuclear cells in gel dressing
- Active Substance
- Autologous bone marrow mononuclear cells
- Modality
- Cell therapy
Related trials
Other published trials that may interest you.